N-([1,4]benzodioxan-2-ylmethyl)-N-(3-chloro-1-propyl)-amine
US6248907A · kind A · utility
Assignee
Inventors
- Peter Matyus
- Laszlo Harsing
- Marianne Tapfer nee Karim
- Judit Kosary
- Agnes Papp nee Behr
- Antal Simay
- Yemane Tilahun
- Eva Tomori nee Joszt
- Edit Horvath
- Katalin Horvath
- Ildiko Varga
- Erzsebet Zara nee Kaczian
- Margit Bidlo nee Igloy
- Alice Druga
- Gyorgy Rabloczky
- Marta Varga
- Egon Karpati
- Endre Kasztreiner
- Istvan Kiraly
- Ildiko Mathe nee Gyory
- Gyorgy Mathe
- Laszlo Sebestyen
- Nandor Makk
Key dates
| Filing date | Aug 28, 2000 |
| Grant date | Jun 19, 2001 |
| Priority date | — |
| Expiry date | Aug 28, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D319/20
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to R-2-[3-([1,4]benzodioxan-2-ylmethylamino)-1-propyl]-3(2H)-pyridazinone of formula (1), and to S-2-[3-([1,4]benzodioxan-2-ylmethylamino)-1-propyl]-3(2H)-pyridazinone of formula (2), and to acid-addition salts thereof as well as pharmaceutical compositions containing these compounds. Furthermore, the invention relates to a process for the preparation of the above compounds. The new starting compounds of formulae (4) and (5) are also involved in the scope of the invention. The compounds according to the invention possess .alpha..sub.1 - and .alpha..sub.2 -adrenoceptor antagonistic effects and urogenital selectivity. Thus, they are useful for the treatment of the benign prostate hyperplasia. ##STR1##
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.